

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: August 13, 2024
PDL Changes Effective Date: October 1, 2024



The following changes will be made to the Preferred Drug List (PDL), effective October 1, 2024, pending approval by the P&T Committee, DOM, and DOM's Executive Director.

NEW PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for PREFERRED STATUS
Cytokine & Cam Antagonists	Tyenee (tocilizumab-aazg)
Movement Disorder Agents	Ingrezza Sprinkle Cap (valbenazine)
Opiate Dependence Treatments (Treatment)	Rextovy (naloxone)

NEW NON-PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for NON-PREFERRED STATUS
Anticonvulsants (Selected Benzodiazepines)	Libervant (diazepam)
Antineoplastics – Selected Systemic Enzyme Inhibitors	Ojemda (tovorafenib)
Cytokine & Cam Antagonists	Rinvoq LQ (upadacitinib)
Cytokine & Cam Antagonists	Simlandi (adalimumab-ryvk)
Cytokine & Cam Antagonists	Tofidence (tocilizumab-bavi)
Factor Deficiency Products (Factor IX)	Beqvez (fidanacogene elaparvovec-dzkt)
Immunosuppressive (Oral)	Myhibbin (mycophenolate mofetil)
Pulmonary Antihypertensives (Activin Signaling Inhibitor)	Opsynvi (macitentan/tadalafil)
Pulmonary Antihypertensives (Combination Agents)	Winrevair (sotatercept-csrk)